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MEKK2 and MEKK3 are MAPK kinase kinases that
activate the ERK5 pathway by phosphorylating and ac-
tivating the MAPK kinase, MEK5. Activated MEK5 then
phosphorylates and activates ERK5. PB1 domains were
first defined in the p67phox and Bem1p proteins and have
been shown to mediate protein-protein heterodimeriza-
tion. A PB1 domain is encoded within the N-terminal
portion of MEKK2, MEKK3, and MEK5. Herein, we ana-
lyze the functional role of MEKK2, MEKK3, and MEK5
PB1 domains in the ERK5 activation pathway. The PB1
domains of MEKK2 and MEKK3 bind the PB1 domain of
MEK5 but do not significantly homo- or heterodimerize
with one another in vitro. Furthermore, co-immunopre-
cipitation of MEKK2 and MEK5 from cell lysates shows
that they form a complex in vivo. Deletion or mutation of
the MEKK2 PB1 domain abolishes MEKK2-MEK5 com-
plexes, demonstrating that the PB1 domain interaction
is required for MEKK2-MEK5 interactions. Expression
in cells of the MEKK2 or MEKK3 PB1 domain inhibits
ERK5 activation, whereas expression of a mutant
MEKK2 unable to bind the MEK5 PB1 domain or expres-
sion of the p67phox PB1 domain has no effect on ERK5
activation. These findings demonstrate that the PB1 do-
main mediates the association of MEKK2 and MEKK3
with MEK5 and that the respective PB1 domains of these
kinases are critical for regulation of the ERK5 pathway.
The free PB1 domain of MEKK2 or MEKK3 functions
effectively to inhibit the ERK5 pathway but not the p38
or JNK pathways, demonstrating the specific and
unique requirement of the MEKK2 and MEKK3 PB1 do-
main in regulating ERK5 activation.
The phox and Bem1p domain, referred to as the PB11 domain,
functions in mediating protein-protein heterodimerization (1).
The PB1 domain is found in proteins of yeast, plants, and meta-
zoans. The PB1 domain was first identified in p67phox, which is
involved in activation of phagocyte NADPH oxidase (2, 3), and
Bem1p, the yeast protein functioning in cell polarity (4). Within
the sequence of most PB1 domains is encoded the PC motif (phox
and Cdc motif) (5), also called OPR (octicosapeptide repeat motif)
(6), or AID (atypical PKC interaction motif) (7), which has been
recently renamed the OPCA (OPR/PC/AID) motif (1). OPCA mo-
tifs are encoded in the C-terminal region of most PB1 domains.
PB1 domains have been shown to heterodimerize using a  grasp
topology in a “front-to-back” arrangement (8). Acidic clusters of
amino acids in the OPCA motif interact electrostatically with
basic clusters in the PB1 domain. Of the mouse and human PB1
domain-encoding proteins, five are serine-threonine kinases:
MEKK2, MEKK3, MEK5, and two atypical protein kinase C
(aPKC) enzymes, PKC and PKC.
MEK5 is the MAPK kinase that phosphorylates and acti-
vates ERK5 in response to growth factors, oxidative stress, and
hyperosmotic conditions (9–14). MEKK2 and MEKK3 are
MAPK kinase kinases that bind, phosphorylate and activate
MEK5 (15, 16). MEKK2 and MEKK3 encode PB1 domains
within their N-terminal sequences (8, 17). Our previous studies
using yeast two-hybrid analysis had shown that the N termi-
nus of MEKK2 is required for its binding to MEK5 (15). The
PB1 domain of MEKK2 is encoded within the N terminus of
MEKK2, suggesting that the PB1 domain contributes to
MEKK2 interaction with MEK5. Therefore, we hypothesized
that the PB1 domains were involved in the interaction of
MEKK2 and MEKK3 with MEK5. Herein, we demonstrate that
the PB1 domain of MEKK2 or MEKK3 specifically interacts
with the PB1 domain of MEK5. Furthermore, expression of the
MEKK2 or MEKK3 PB1 domain in cells inhibits ERK5 activa-
tion. Taken together, our findings show that the PB1 domain
confers specificity in the interaction of MEKK2 and MEKK3
with MEK5 and that an isolated MEKK2 or MEKK3 PB1
domain behaves as an inhibitor of the ERK5 pathway.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—Wild type and MEKK2/ mouse em-
bryonic fibroblasts (MEFs) were isolated as described previously (18).
DNA Constructs—The cDNAs for the conserved PB1 domains of
MEKK2 (amino acids (aa) 35–127), MEKK3 (aa 36–128), MEK5 (aa
10–102), and p67phox (aa 342–433) were amplified using PCR and
ligated into pGEX, pRSET, and pMSCVpuro vectors. For the pMSCV-
puro constructs, a FLAG tag was inserted upstream of the PB1
domain coding sequence. For the MEKK2 PB1 domain mutation
constructs, amino acid residue lysine (Lys) 47 was replaced by ala-
nine (Ala) using a site directed mutagenesis. Wild type, Lys to Ala
mutant (K-A MEKK2), and PB1 domain deleted MEKK2 (PB1
MEKK2) (aa 123–619) were subcloned into the pMSCVpuro vector.
FLAG-MEK5, HA-MEKK2, and HA-MEKK3 constructs were
described previously (15).
Generation of Cell Lines Expressing FLAG-PB1 Domains and
MEKK2 Proteins—Phoenix cells were used as packaging cells for the
retroviral gene transfer system (19). pMSCVpuro vectors were trans-
fected into Phoenix cells using Lipofectamine Plus transfection reagent
(Invitrogen). Two days after transfection, the supernatants were col-
lected and diluted with the same volume of fresh complete IMDM, and
polybrene was added to the infection medium at 8 g/ml. The infection
mixtures were added to MEF cultures seeded on 6-cm dishes, incubated
overnight, and then replaced with fresh complete IMDM containing 50
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g/ml puromycin. The puromycin-resistant cells were isolated and
propagated for use in the experiments.
RESULTS
PB1 Domains of MEKK2, MEKK3, and MEK5—Previously,
we demonstrated in a yeast two-hybrid screening that the N
terminus of MEKK2 encoding amino acids 1–188 bound to MEK5
(15). Furthermore, truncation of the first 125 amino acids of
MEKK2 resulted in loss of MEK5 binding. The PB1 domain of
MEKK2 is encoded within amino acids 43–122, consistent with
this region of MEKK2 being important for the interaction be-
tween MEKK2 and MEK5. Fig. 1A shows the sequence align-
ment of the MEKK2, MEKK3, MEK5, p67phox PB1 domains
compared with yeast Bem1p PB1 sequence. Although the PB1
domain structure is highly similar to the Ras binding domain of
c-Raf1 (4), PB1 domains have not been found to bind Ras pro-
teins. PB1 dimers have recently been described as having a 
grasp topology with a front-to-back binding arrangement (8). The
OPCA motif is a conserved sequence in the C-terminal moiety of
the PB1 domain (1). It is worth noting that MEKK2 and MEKK3
have rather weak consensus OPCA motifs. Acidic clusters of
amino acids in the OPCA motif of one PB1 domain bind to basic
amino acids including the conserved Lys residue in the N-termi-
nal moiety of a different PB1 domain. Mutation of the conserved
Lys residue in Bem1p and p67phox was shown to completely
disrupt its binding to Cdc24p and p40phox, respectively (2). The
defined function of PB1 domains appears to compose het-
erodimerization of the cognate proteins.
To characterize the properties of the MEKK2, MEKK3, and
MEK5 PB1 domains, we expressed each PB1 domain as a
GST-fusion and His/Xpress-tagged recombinant protein (Fig. 1,
B–D). The p67phox PB1 domain was also expressed as a control
for binding studies presented below. In addition, to see the role
of the conserved Lys residue, a MEKK2 PB1 domain construct
having Ala substituted for Lys47 was also prepared. The recom-
binant PB1 domain proteins were then used to define their abil-
ity to form hetero- or homodimeric complexes using pull-down
assays and immunoblotting (Fig. 1, B and C). The MEKK2 PB1
domain bound MEK5. However, the association seemed less sta-
ble when the MEKK2 PB1 domain was expressed as a His/
Xpress-tagged protein and MEK5 PB1 domain as a GST fusion
than the reciprocal expression of the fusion proteins (compare
Fig. 1, B and C). The reason for this difference is unclear but may
be related to some differential interfering effect of GST and
His/Express tag portions on PB1 domain function. Importantly,
the K-A MEKK2 mutant PB1 domain or the p67phox PB1 domain
did not bind to MEK5. The MEKK3 PB1 domain also bound the
MEK5 but not the p67phox or MEKK2 PB1 domain. Cumula-
tively, these findings indicate a selective interaction of the
MEKK2 and MEKK3 PB1 domains with the MEK5 PB1 domain.
Pull-down of MEK5 from Lysates of Mouse Embryo Fibro-
blasts—Fig. 2A shows that the PB1 domains of MEKK2 and
MEKK3 bind to endogenous MEK5 from lysates of wild type
MEFs. The p67phox, K-A MEKK2 mutant, and MEK5 PB1
domains failed to bind and pull-down MEK5 from MEF lysates.
To verify the binding of endogenous MEK5 to MEKK2 and
MEKK3 PB1 domain, a FLAG-tagged MEK5 was expressed in
MEFs (Fig. 2B). Similar to endogenous MEK5, expressed
MEK5 could be selectively pulled down by the MEKK2 and
MEKK3 PB1 domains but not the p67phox, K-A MEKK2 mu-
tant, or MEK5 PB1 domain. Similarly when MEKK2 or
MEKK3 were expressed in cells, the MEK5 PB1 domain was
able to pull down MEKK2 (Fig. 2C) and MEKK3 (Fig. 2D).
These data clearly demonstrate that in mammalian cells the
MEKK2 and MEKK3 PB1 domains selectively bind to MEK5
and vice versa, the MEK5 PB1 domain selectively binds
MEKK2 and MEKK3. The PB1 domains do not appear to
significantly bind to themselves (homodimeric interactions).
The modest pull-down of HA-MEKK3 with the MEKK3/
MEKK2 PB1 domains in Fig. 2D may suggest that an in vivo
FIG. 1. Interaction of MEKK2, MEKK3, and MEK5 PB1 do-
mains in vitro. A, sequence alignment of the mouse MEKK2, MEKK3,
MEK5, and p67phox PB1 domains and OPCA motifs with yeast Bem1p
sequence. The conserved lysine in PB1 domain is in gray. This Lys
residue is substituted with Ala in the K-A MEKK2 mutant. Shading
indicates conserved OPCA sequence (h, hydrophobic amino acid). Con-
sensus PB1 domain sequence is based on an alignment of the known
PB1 domain-containing proteins. B and C, GST pull-down assays to
measure the in vitro binding of GST fusions of the PB1 domains of
MEKK2, K-A MEKK2, MEKK3, MEK5, and p67phox with His/Xpress-
tagged PB1 domains of the same proteins. Pull-down assays were
conducted with the indicated GST-PB1 domain fusion protein and His/
Xpress-tagged protein. The adsorbents were immunoblotted with anti-
Xpress Ab. D, anti-Xpress Ab blot of 1% of the total His/Xpress-tagged
protein used for each pull-down assay, demonstrating similar expres-
sion of each protein.
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complex of MEK5 and MEKK3/MEKK2 proteins exists in cells,
since bacterially expressed, recombinant MEKK3 PB1 domain
did not bind itself, MEKK2, or p67phox PB1 domains (Fig. 1).
MEKK2 PB1 Domain Is Required for Co-immunoprecipita-
tion of MEKK2 and MEK5—MEKK2/ MEFs (18) were used
to add back wild type MEKK2, K47A mutated MEKK2 (K-A
MEKK2), or a MEKK2 protein whose PB1 domain had been
deleted (PB1 MEKK2). A MEKK2 monoclonal antibody was
then used to immunoprecipitate the different MEKK2 proteins.
Fig. 3 shows that only the wild type MEKK2 protein was
capable of constitutively associating with MEK5 for co-immu-
noprecipitation. Neither the K-A mutant that disrupts PB1
domain binding nor the PB1 MEKK2 protein bound MEK5.
These findings indicate that the MEKK2 PB1 domain is re-
quired for stable association of MEKK2 and MEK5.
MEKK2 and MEKK3 PB1 Domains Bind MEK5 in Vivo and
Inhibit ERK5 Activity—To examine the functional consequence
of expressing the free PB1 domains of MEKK2, MEKK3, and
MEK5 on the ERK5 signaling pathway, FLAG-tagged MEKK2,
K-A MEKK2, MEKK3, and p67phox PB1 domains were ex-
pressed in MEFs. Unfortunately, we were unable to express the
FLAG-tagged MEK5 PB1 domain in MEFs (data not shown).
The MEKK2, K-A MEKK2, MEKK3, and p67phox FLAG-tagged
proteins were efficiently expressed in MEFs. FLAG-MEKK2
and FLAG-MEKK3 PB1 domains bound endogenous MEK5 as
shown by co-immunoprecipitation (Fig. 4A). In contrast, nei-
ther the mutant K-A MEKK2 nor p67phox PB1 domain inter-
acted with MEK5 (Fig. 4A). Total cell lysates prepared from the
different FLAG-PB1 domain expressing cells were used to
measure ERK5 activity. The level of ERK5 activity was as-
sessed by a mobility shift of the ERK5 band in the gels (Fig.
4B). The slower migrating band of the ERK5 doublet has been
shown to be caused by ERK5 phosphorylation that correlates
with its activation (16, 20, 21). In the presence of 10% serum,
ERK5 activation was readily observed in MEFs. Neither
FLAG-K-A MEKK2 nor FLAG-p67phox PB1 domain showed any
inhibitory activity toward the ERK5 mobility shift. In contrast,
both FLAG-MEKK2 and FLAG-MEKK3 PB1 domains com-
pletely blocked ERK5 activation.
FLAG-MEKK2 and FLAG-K-A MEKK2 PB1 domain ex-
pressing cells were further analyzed with sorbitol stimulation,
a hyperosmotic stress that activates ERK5 in a MEKK2-de-
pendent manner (14) (Fig. 4C). Sorbitol induced an ERK5 mo-
bility shift in control and FLAG-p67phox PB1 domain express-
ing MEFs. This mobility shift was abolished by expression of a
FLAG-MEKK2 PB1 domain, but not by expression of the
FLAG-K-A MEKK2 PB1 domain. Cumulatively, these data
indicate that an expressed MEKK2 or MEKK3 PB1 domain
binds to endogenous MEK5 and induces a refractory state of
the MEKK2 or MEKK3/MEK5/ERK5 signaling pathway so
that ERK5 is not activated. Importantly, sorbitol activation of
p38 MAPK or JNK was not inhibited by expression of the
MEKK2 PB1 domain (Fig. 4C). Thus, the inhibitory effect of the
MEKK2 PB1 domain is specific for the ERK5 pathway.
DISCUSSION
MEKK2 and MEKK3 are unique among the MAPK kinase
kinases in their ability to regulate the ERK5 pathway (15). No
other MAPK kinase kinase has been shown to regulate MEK5
and activation of the ERK5 pathway. Interestingly, it has been
reported that PKC phosphorylates MEK5 and activates the
ERK5 pathway (22), although this result has been recently
disputed (17). Our work indicates that the specificity of
MEKK2 and MEKK3 regulation of the ERK5 pathway resides
in the PB1 domains encoded in the N-terminal region of
MEKK2, MEKK3, and MEK5. The PB1 domain of MEKK2 or
MEKK3 specifically heterodimerize with the PB1 domain of
MEK5. A functional PB1 domain is absolutely necessary for
interaction of full-length MEKK2 with endogenous MEK5. Mu-
tation of the conserved Lys residue, which inhibits PB1 domain
binding, or deletion of the PB1 domain in MEKK2 abolishes
MEKK2 binding to MEK5. Furthermore, a free MEKK2 or
MEKK3 PB1 domain inhibits ERK5 activation in response to
serum or hyperosmotic stress. This result is striking and
strongly suggests that the PB1 domain interaction of MEKK2
or MEKK3 with MEK5 is required for MEK5 activation of
ERK5. Disruption of the MEKK2 and MEKK3 interaction with
MEK5 using the free PB1 domains appears to be sufficient to
inhibit the ERK5 pathway. It should be noted that when we
overexpressed wild type MEKK2, K-A MEKK2, or PB1
MEKK2, ERK5 became activated (data not shown). This indi-
cates that overexpression of MEKK2 proteins even lacking a
functional PB1 domain could still activate the ERK5 pathway,
suggesting that the overexpression of these proteins predict-
ably bypasses the need for normal assembly of a regulatory
complex. It is clear from our previous studies that MEKK2
expression is required for the activation of the ERK5 pathway
by growth factors and oxidative and hyperosmotic stresses (14,
15). The targeted gene disruption of MEKK2 abolishes ERK5
activation to these stimuli (14), and we now demonstrate that
the free MEKK2 or MEKK3 PB1 domain inhibits endogenous
ERK5 activation.
Our studies with MEKK2/ MEFs, where we created a
MEKK2 knockout by targeted disruption of the MEKK2 gene,
has shown that MEKK2 coordinately regulates the ERK5 and
JNK pathways (14). MKK7, the MAPK kinase that regulates
JNK, has been characterized to bind to the C-terminal region of
FIG. 2. Binding of full-length MEK5, MEKK2, and MEKK3 by
the PB1 domains of MEKK2, MEKK3, and MEK5. GST-PB1 domain
fusion proteins were used for the pull down assays from MEF lysates. A,
immunoblot of endogenous MEK5 pulled down from MEF lysates. B,
immunoblot of FLAG-MEK5 pulled down from FLAG-MEK5 trans-
fected MEF lysates. C, immunoblot of HA-MEKK2 pulled down from
HA-MEKK2 transfected MEF lysates. D, immunoblot of HA-MEKK3
pulled down from HA-MEKK3 transfected MEFs. For each pull-down
assay 1 mg of total MEF lysate was used for A–D.
FIG. 3. MEKK2 PB1 domain interaction with MEK5 in vivo.
Wild type (WT), K-A MEKK2, and PB1 MEKK2 were expressed in
MEKK2/ MEFs using retroviral transfection. MEKK2 protein was
immunoprecipitated from the cells using an anti-MEKK2 mAb. The
immunocomplexes were analyzed by anti-MEK5 blotting.
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MEKK2 (20, 23), whereas MEK5 binds to the N-terminal PB1
domain of MEKK2. Thus, the MAPK kinases for the JNK and
ERK5 pathways bind different regions of MEKK2. Loss of
MEKK2 expression in mouse embryo fibroblasts results in loss
of ERK5 activation in response to growth factors such as FGF-2
and both oxidative and hyperosmotic stresses (18). Normal
JNK activation in the presence of free MEKK2 PB1 domain
demonstrates that MEK5 PB1 domain interaction with the
PB1 domain of MEKK2, MEKK3, or other proteins is not
needed for the MEKK2-mediated regulation of JNK activation.
Similarly, expression of MEKK2 or MEKK3 PB1 domains has
no inhibitory effect on p38 activation, consistent with the PB1
domain of MEKK2, MEKK3, and MEK5 functioning in the
regulation of ERK5, but not JNK or p38 activation.
During the course of these studies, Lamark et al. (17) re-
ported that MEK5 bound to the adapter protein, p62, via PB1-
PB1 domain interactions. The p62 adapter protein has been
shown to be important in forming a complex with TrkA, the
neurotrophic receptor tyrosine kinase, and to be critical for
neurotrophin activation of the ERK5 pathway (24). It has been
proposed that p62 is critical for forming a signaling complex in
endosomes that also includes the aPKCs (25) and that these
responses are critical for neuronal differentiation (24, 26). It is
presently unclear if MEKK2 or MEKK3 is associated with the
p62-aPKC-MEK5 complex. Certainly, a model could easily be
envisioned where PB1 domains of p62, MEK5, MEKK2, and/or
MEKK3 along with the aPKCs might form an oligomeric sig-
naling complex.
In conclusion, our results, for the first time, show the specific
interaction of the MEKK2 and MEKK3 PB1 domains with the
MEK5 PB1 domain. Expression of the MEKK2 or MEKK3 PB1
domain selectively inhibited ERK5 but not JNK or p38 activa-
tion. The fact that mutation of the conserved Lys to Ala in the
MEKK2 and MEKK3 PB1 domains inhibited interaction with
the MEK5 PB1 domain, and resulted in the failure to inhibit
ERK5 activation in cells, is consistent with very specific se-
quence requirements that are necessary for the selective PB1-
OPCA interactions we and others (8, 17) have observed.
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FIG. 4. MEKK2 and MEKK3 FLAG-PB1 domains interact with
MEK5 and inhibit ERK5 activation. FLAG-tagged MEKK2, K-A
MEKK2, MEKK3, or p67phox PB1 domains was expressed in MEFs. A,
anti-MEK5 immunoblot of FLAG Ab immunoprecipitates from cells
expressing the indicated FLAG-tagged PB1 domains. Left and right
panels show anti-MEK5 Ab and FLAG Ab immunoblots, respectively. B,
ERK5 mobility shift assay of the indicated PB1 domain expressing
MEFs grown in 10% serum. C, FLAG-PB1 domain expressing MEFs
were serum starved for 12 h and then stimulated with 0.2 M sorbitol for
20 min, and the ERK5 mobility shift was analyzed by anti-ERK5 Ab
immunoblotting. The activation of p38 and JNK was analyzed by im-
munoblotting with phospho-specific antibodies for p38 and JNK,
respectively.
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